APA (7th ed.) Citation

Geva, M., Reilmann, R., Feigin, A., Rosser, A., Kostyk, S., Chen, K., . . . Hayden, M. R. The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease (HD). Elsevier.

Chicago Style (17th ed.) Citation

Geva, Michal, Ralf Reilmann, Andrew Feigin, Anne Rosser, Sandra Kostyk, Kelly Chen, Yael Cohen, Y Paul Goldberg, and Michael R. Hayden. The Phase 3 PROOF-HD Trial Demonstrates Persistent Benefits of Pridopidine on Function, Cognition, and Motor Function Through the 6 Month Open Label Extension in Huntington Disease (HD). Elsevier.

MLA (9th ed.) Citation

Geva, Michal, et al. The Phase 3 PROOF-HD Trial Demonstrates Persistent Benefits of Pridopidine on Function, Cognition, and Motor Function Through the 6 Month Open Label Extension in Huntington Disease (HD). Elsevier.